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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A360eligibility and safety ﬁndings relevant for aNGF clinical trials. More than
400 images were reviewed to deﬁne the most relevant and character-
istic imaging ﬁndings.
Diagnoses of exclusion for eligibility due to potentially increased risk of
RPOA are subchondral insufﬁciency fractures (SIF), atrophic OA and
severe malalignment of the knee in the medial-lateral direction. Diag-
noses relevant for safety after enrolment (i.e. joint safety ﬁndings), i.e.
RPOA, SIF, osteonecrosis and pathologic fractures will also be discussed.
Several of these diagnoses have non-speciﬁc ﬁndings on the radiograph
or cannot be detected radiographically in early stages. Thus, in cases of
inconclusive or suspicious radiography, an additional MRI examination
may be acquired to rule out or conﬁrm some of these diagnoses.
Results: Early and late signs of diagnoses relevant for eligibility will be
presented.
Fig 3A. Radiograph of the hip joint shows superior JSN (arrows) without
relevant osteophytes present.Fig 3B. Follow up image 12 months later shows near-complete destruc-
tion of the femoral head (arrows) and subsequent migration of the femur
superiorly consistent with RPOA.
Conclusions: Expert readers in aNGF programs need to be aware of
relevant imaging ﬁndings. These include early signs of diagnoses rele-
vant for RPOA on radiography, and other potential X-ray and MRI
diagnoses relevant for eligibility and safety during aNGF studies.
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PROLONGED JOINT RESIDENCY OF TRIAMCINOLONE ACETONIDE
AFTER AN INTRA-ARTICULAR INJECTION OF FX006, A SUSTAINED
RELEASE FORMULATION FOR THE TREATMENT OF OSTEOARTHRITIS
N. Bodick y, J. Lufkin y, C. Willwerth y, J. Hauben y, A. Kumar y, P. Boen y,
J. Bolognese z, C. Schoonmaker z, M. Clayman y. y Flexion Therapeutics,
Burlington, MA, USA; zCytel Inc, Cambridge, MA, USA
Purpose: Although available intra-articular (IA) corticosteroids are well
established in the treatment of painful osteoarthritis (OA), limitations
include short duration of pain relief (1-4 weeks), an effect consistent
with the transient residency of these compounds in the joint and high
plasma corticosteroid concentrations immediately following injection.
FX006 is a novel IA sustained-release injectable formulation of 25%
triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid) micro-
spheres intended to prolong therapeutic concentrations of TCA in the
joint and limit systemic exposure. In a previously described 6-week
long clinical study, FX006 at 40 mg demonstrated maintenance of
synovial concentrations of TCA consistent with pharmacologic activity
for a period of at least 6 weeks, when levels of TCA produced by an
equivalent dose of TCA IR were below the limit of quantitation. The
current study extended these data on joint residency by measuring
synovial ﬂuid levels of TCA at later time points.
Methods: In this multi-center, open-label study, patients with OA of the
knee received a single IA injection of FX006 containing 10 or 40mg TCA,
or 40mg of a standard, immediate-release suspension of TCA (TCA IR). A
total of 50 patients were enrolled (FX006 10 mg: 10 patients, FX006 40
mg: 30 patients, TCA IR: 10 patients). Synovial ﬂuid and plasma samples
were obtained at baseline (pre-dose) and at the planned Final Visit at
either Week 12, 16, or 20, depending on cohort assignment and avail-
ability of ﬂuid in the knee. Concentrations of TCA were measured in
plasma or in ﬁltered synovial ﬂuid samples using High Performance
Liquid Chromatographic methods with Tandem Mass Spectrometry
Detection and Automated Extraction, validated for the determination of
TCA in human plasma and synovial ﬂuid respectively. The quantitation
limits of both assays were 50 to 50000 pg/mL.
Results: In the FX006 10 mg group, 8 patients had synovial ﬂuid
available for analysis at Week 12. In the FX006 40 mg group, 6 patients
had synovial ﬂuid available for analysis at Week 12, 8 patients at Week
16 and 11 patients at Week 20. In the TCA IR group, 5 patients had
synovial ﬂuid available for analysis at Week 12. The concentrations of
TCA achieved by 40mg FX006 in the synovial ﬂuid atWeek 12 were 924
pg/mL, at Week 16, the IA concentrations of TCAwere 224 pg/mL and by
Week 20 they were below the lower limit of quantitation (Figure;
geometric means from the earlier 6-week study and the current study
are merged). The IA concentration of TCA in patients receiving 40 mg of
TCA IR at Week 12 was below the lower limit of quantitation. FX006
maintained a gradient between synovial and systemic plasma concen-
trations of TCA for 16 weeks.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A361Conclusions: A single IA administration of 40 mg of FX006 maintained
pharmacologically active synovial ﬂuid concentrations of TCA for at
least 12 weeks, while TCA IR produced levels that are below the lower
limit of quantitation by 6weeks. These data underpin the differentiation
of FX006 from TCA IR and provide pharmacokinetic basis for previously
demonstrated prolongation and ampliﬁcation of pain relief compared to
TCA IR in OA patients following a single IA injection. FX006 also has the
potential for an improved systemic safety proﬁle as evidenced by peak
plasma concentrations that are 40-fold lower than TCA IR at the same
dose, seen in the aggregate of clinical studies with FX006 to date.
592
GASTROINTESTINAL SAFETY AND TOLERABILITY OF LONG-TERM
GCSB-5 OF DRIED EXTRACTS OF SIX HERBS IN PATIENTS WITH
OSTEOARTHRITIS: A 24 WEEKS, MULTI-CENTERS, SINGLE ARM
PHASE IV STUDY
C.-W. Ha y, Y.-B. Park y, H.-S. Kyung z, H.-C. Lim x, S.-E. Park k,
M.-C. Lee ¶, Y.-Y. Won#, D.-C. Lee yy, C.-W. Kim zz, J.-G. Kim xx,
J.-S. Kang kk, J.-K. Seon ¶¶, S.-I. Bin ##. y Samsung Med. Ctr.,
Sungkyunkwan Univ. Sch. of Med., Seoul, Republic of Korea; zKyungpook
Natl. Univ. Hosp., Kyungpook Natl. Univ. Sch. of Med., Daegu, Republic of
Korea; xKorea Univ. Guro Hosp., Korea Univ. Sch. of Med., Seoul,
Republic of Korea; kDongguk Univ. Intl. Hosp., Dongguk Univ. Sch. of
Med., Goyang, Republic of Korea; ¶ Seoul Natl. Univ. Hosp., Seoul Natl.
Univ. Sch. of Med., Seoul, Republic of Korea; #Ajou Univ. Hosp., Ajou
Univ. Sch. of Med., Suwon, Republic of Korea; yy Yeungnam Univ. Hosp.,
Yeungnam Univ. Univ. Sch. of Med., Daegu, Republic of Korea; zzBusan
Paik Hosp., Inje Univ. Sch. of Med., Seoul, Republic of Korea; xx Seoul Paik
Hosp., Inje Univ. Sch. of Med., Seoul, Republic of Korea; kk Inha Univ.
Hosp., Inha Univ. Sch. of Med., Incheon, Republic of Korea; ¶¶Chonnam
Natl. Univ. Hwasun Hosp., Chonnam Natl. Univ. Sch. of Med., Hwasun,
Republic of Korea; ##Asan Med. Ctr., Ulsan Univ. Sch. of Med., Seoul,
Republic of Korea
Purpose: A previous study on GCSB-5 was shown to be non-inferior to
Celecoxib in efﬁcacy and safety in treating osteoarthritis, but its safety
information on the gastrointestinal (GI) safety is limited to only 12weeks.
A longer term (24 weeks) study with a larger number of patients is nec-
essary to establish the GI safety of GCSB-5. The primary goal of this study
was to determine the incidence of GI disorders associated with GCSB-5.
The secondary goal was to collect 24-week safety data of GCSB-5.
Methods: A single arm safety study on 24-week GCSB-5 was conducted.
Additionally, the results of this study were compared with Historical
Data of Celecoxib. This study was performed in 19 academic institutions
between May 2012 and June 2013. Two GCSB-5 capsules (300 mg per
capsule) were prescribed two times per day for 24weeks. Incidence of GI
disorders was the primary outcome. Incidence of GI perforation, ulcer
obstruction and bleeding (PUB), gastroduodenal ulcer, and dropout due
to GI complications were the major secondary outcome variables.
Results: A total of 761 patients with osteoarthritis were enrolled and
756 patients took at least one dose of study drug. A total of 629 patients
(82.7%) completed the 24 weeks follow-up visit. The incidence of GI
disorders among the 756 patients with or without aspirin exposure was
23.7%. Aspirin use did not show any signiﬁcant difference in GI dis-
orders. The annualized incidence rate of PUB was 0.0%. The annualized
incidence rate of gastroduodenal ulcer was 0.0%. The drop-out rate due
to GI disorders in GCSB-5 was 4.8%. As the results compared with His-
torical Data of Celecoxib, the incidence of GI disorders (29.9%),
annualized rate of PUB and gastroduodenal ulcer (2.2%), and drop-out
rate (8.7%) due to GI disorders for Celecoxib were signiﬁcantly higher
than GCSB-5.
Conclusions: This study indicated GCSB-5 was safe for patients with
osteoarthritis during long-term treatment. Furthermore, the safety
results of GCSB-5 associated with GI disorder were comparable to
Celecoxib.
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THE EFFECT OF PREOPERATIVE PAIN TREATMENT BY MEANS OF
DULOXETINE ON POSTOPERATIVE OUTCOME AFTER TOTAL HIP OR
KNEE ARTHROPLASTY: DESIGN OF A PRAGMATIC RANDOMIZED
CONTROLLED TRIAL
T. Blikman y, W. Rienstra y, T.M. van Raaij z, S.K. Bulstra y, M. Stevens y,
I. van den Akker-Scheek y. yUniv. Med. Ctr. Groningen, Groningen,
Netherlands; zMartini Hosp. Groningen, Groningen, NetherlandsPurpose: Total joint replacement (TJR) is considered to be one of the
most safe, successful, and cost-effective treatments for advanced
osteoarthritis (OA). However, residual pain seems to be a major factor of
patient’s dissatisfaction following Total Hip Arthroplasty/Total Knee
Arthroplasty (THA/TKA). The proportion of patients suffering from
unfavourable long-term residual pain is relatively high, proportions
ranging from 10 to 34% after knee and 7 to 23% after hip replacement
surgery. Changes within the central nervous system are presumably
accountable for accessory pain ampliﬁcation and sensitization. Cur-
rently there are studies indicating that a preoperative degree of central
sensitisation (CS) is associated with poorer postoperative outcomes and
residual pain. Thus, it could be hypothesized that preoperative treat-
ment of CS could enhance postoperative outcomes. Duloxetine, a
combined serotonin and norepinephrine reuptake inhibitor (SNRI), has
shown to be effective in several chronic pain syndromes, including
knee-OA, in which CS is likely one of the underlying pain mechanisms.
This study aims to evaluate the postoperative effects of preoperative
screening and targeted duloxetine treatment of CS on residual pain,
compared to care as usual.
Methods: This multi-centre, pragmatic, prospective, open-label,
randomized controlled trial (RCT) includes adults which are on the
waiting list for primary THA/TKA, with a possible or likely neuropathic
pain (NP) phenotype at screening (deﬁned by a score >12 point on the
modiﬁed-painDETECT questionnaire), hence this will probably identify
patients who are more likely to experience CS. Patients will be ran-
domly allocated to the preoperative “duloxetine treatment group” (1
week initiation 30 mg/d, 7 weeks 60 mg/d, 2 weeks taper-phase 30 mg/
d) or the “care as usual group” (no speciﬁc preoperative intervention).
The primary endpoint is the degree of postoperative pain 6 months
after THA/TKA, assessed with the pain subscale of the Hip disability/
Knee injury and Osteoarthritis Outcome Score (HOOS/KOOS). Secondary
endpoints, at multiple pre- and postoperative time points (up to 12
months postoperative) will be; pain, neuropathic pain (NP), sensitisa-
tion (pressure pain thresholds, temporal summation), quality of life and
depressive/anxiety symptoms. Furthermore, factors such as perceived
satisfaction and arthroplasty related expectations will be analyzed.
Based on a minimally clinical important difference of 10 points on the
HOOS/KOOS; a total of 118 patients are anticipated to be randomized to
detect a clinical relevant difference (80% power, 20% protocol violators
and/or dropout included).
Results: Data analysis will be conducted on an intention-to-treat basis.
In case of the primary endpoint a Student’s t-test (or a non-parametric
equivalent in case of a skewed distribution) will be used to determine if
there is a difference in pain on the HOOS/KOOS at 6 months post-
operative between the two groups. GEE (Generalized Estimating
Equation) analysis will be used to determine whether there is a differ-
ence on pain between the two groups over time, adjusted for relevant
covariates. The same principles will be used to asses the secondary time
points. A P-value of < 0.05 is considered statistically signiﬁcant.
Conclusions: This study is, as far as we know, the ﬁrst pragmatic RCT
assessing the postoperative effects of a preoperative targeted dulox-
etine treatment in OA-patients suffering from a degree of preoperative
CS (indicated by a possible or likely NP-phenotype). We believe a
pragmatic trial design is valid; hence it mimics the “real life status”,
with a “care as usual” control group, as much as possible. Furthermore,
the endpoints are, unlike placebo controlled explanatory trials, more
focused on the relevancy to everyday life; like hip and knee speciﬁc
pain, function and quality of life. Knowledge gained with this study can
potentially improve postoperative pain relief and rehabilitation after
TJR.
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DIFFERENTIAL PROFILING OF SECRETOMES FROM HUMAN
CARTILAGE TO IDENTIFY POTENTIAL EARLY SPECIFIC PROTEIN
BIOMARKERS IN OSTEOARTHRITIS
L. Lourido, V. Calamia, P. Fernandez-Puente, J. Mateos, B. Rocha,
C. Fernandez-Costa, C. Fernandez-Lopez, N. Oreiro, F.J. Blanco,
C. Ruiz-Romero. INIBIC e CHU A Coru~na, A Coru~na, Spain
Purpose: Osteoarthritis (OA) is characterized by the progressive loss of
cartilage structural extracellular matrix (ECM) components. The release
of these proteins from the tissue can vary according to the stage of the
disease and the speciﬁc joint affected. The aim of this study was to
